A β-secretase modulator decreases Tau pathology and preserves short-term memory in a mouse model of neurofibrillary degeneration

Archive ouverte

Tautou, Marie | Eddarkaoui, Sabiha | Descamps, Florian | Larchanché, Paul-Emmanuel | Dumoulin, Mélanie | Lamarre, Chloé | Blum, David | Buée, Luc | Melnyk, Patricia | Sergeant, Nicolas

Edité par CCSD -

Abstract A structure-activity relationship has enabled us to identify two molecules, MAGS02-14 and PEL24-199, sharing a β-secretase modulatory effect but having or not a lysosomotropic activity, respectively. More importantly, MAGS02-14 and PEL24-199 only differ from each other by a single nitrogen atom. However, which of the lysosomotropic and/or β-secretase modulating activities is necessary for the pharmacological effect in vivo remains ill-defined. To address this question, the THY-Tau22 transgenic model of NFD was treated for 6 weeks in a curative paradigm and short-term memory, Tau burden, and inflammatory processes were studied. PEL24-199, possessing only the β-secretase modulatory activity, was shown to restore the short-term memory and to reduce NFD. This effect was associated with reduced phosphorylation of Tau, increased phosphatase expression, and a decrease of astrogliosis. Our results therefore suggest that the lysosomotropic activity may be dispensable for the effect on both Aβ and Tau pathologies.

Consulter en ligne

Suggestions

Du même auteur

A ß-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration

Archive ouverte | Tautou, Marie | CCSD

International audience. Identifying which among several in cellulo pharmacological activities is necessary for the proper in vivo activity is essential for further drug development against Alzheimer’s disease pathop...

A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology

Archive ouverte | Tautou, Marie | CCSD

International audience. The progress in Alzheimer’s disease (AD) treatment suggests a combined therapeutic approach targeting the two lesional processes of AD, which include amyloid plaques made of toxic Aβ species ...

A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors

Archive ouverte | Gay, Marion | CCSD

International audience. Dysregulation of the Amyloid Precursor Protein (APP) processing leading to toxic species of amyloid b peptides (Ab) is central to Alzheimer's disease (AD) etiology. Ab peptides are produced b...

Chargement des enrichissements...